KMT2A and acute myeloid leukemia: Among KMT2A-rearranged AML, t(9;11)(p21.3;q23.3)/KMT2A::MLLT3 are associated with a higher response rate to intensive chemotherapy compared to other translocations [66] and are thus included in the intermediate risk category when using the ELN 2022 classification, unlike the remaining high-risk KMT2A-rearranged subtypes [39].